Overexpression of 14-3-3z promotes tau phosphorylation at Ser 262and accelerates proteosomal degradation of synaptophysin in rat primary hippocampal neurons

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Qureshi, Hamid Y ^a   Han, Dong ^a   MacDonald, Ryen ^a,b   Paudel, Hemant K ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; PACLITAXEL; PROTEIN 14 3 3; PROTEIN 14 3 3Z; PROTEOME; SYNAPTOPHYSIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DOWN REGULATION; GENE OVEREXPRESSION; HIPPOCAMPUS; MICROTUBULE ASSEMBLY; NERVE CELL DIFFERENTIATION; NEUROPATHOLOGY; NEUROTRANSMITTER RELEASE; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEOMICS; SYNAPTOGENESIS;

14-3-3 PROTEINS; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANIMALS; CLONING, MOLECULAR; DNA PRIMERS; GENE EXPRESSION REGULATION; HIPPOCAMPUS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; MICROSCOPY, FLUORESCENCE; MICROTUBULES; MOLECULAR CHAPERONES; NEURONS; PACLITAXEL; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; RATS; SYNAPTOPHYSIN; TAU PROTEINS;

EID: 84893200880     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084615     Document Type: Article

References (101)

1. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24: 1121-1159. doi:10.1146/annurev.neuro.24.1.1121. PubMed: 11520930. (Pubitemid 32695256)
2. Lee G, Leugers CJ (2012) Tau and tauopathies. Prog Mol Biol. Transl Sci 107: 263-293.
3. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, Wszolek Z, Reed L et al. (1998) Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282: 1914-1917. doi:10.1126/science.282.5395.1914. PubMed: 9836646. (Pubitemid 28555275)
4. Vogelsberg-Ragaglia V, Bruce J, Richter-Landsberg C, Zhang B, Hong M et al. (2000) Distinct FTDP-17 missense mutations in tau produce tau aggregates and other pathological phenotypes in transfected CHO cells. Mol Biol Cell 11: 4093-4104. doi:10.1091/mbc.11.12.4093. PubMed: 11102510.
5. Lim F, Hernández F, Lucas JJ, Gómez-Ramos P, Morán MA et al. (2001) FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol Cell Neurosci 18: 702-714. doi:10.1006/mcne.2001.1051. PubMed: 11749044. (Pubitemid 34060150)
6. von Bergen M, Barghorn S, Li L, Marx A, Biernat J et al. (2001) Mutations of tau protein in frontotemporal dementia promote aggregation of paired helical filaments by enhancing local beta-structure. J Biol Chem 276: 48165-48174. PubMed: 11606569.
7. Allen B, Ingram E, Takao M, Smith MJ, Jakes R et al. (2002) Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 22: 9340-9351. PubMed: 12417659. (Pubitemid 35356177)
8. Tanemura K, Murayama M, Akagi T, Hashikawa T, Tominaga T et al. (2002) Neurodegeneration with tau accumulation in a transgenic mouse expressing V337M human tau. J Neurosci 22: 133-141. PubMed: 11756496. (Pubitemid 34033491)
9. Alonso Adel C, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K (2004) Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem 279: 34873-34881. doi:10.1074/jbc.M405131200. PubMed: 15190058. (Pubitemid 39318122)
10. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L et al. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309: 476-481. doi:10.1126/science.1113694. PubMed: 16020737. (Pubitemid 40994688)
11. Han D, Qureshi HY, Lu Y, Paudel HK (2009) Familial FTDP-17 missense mutations inhibit microtubule assembly-promoting activity of tau by increasing phosphorylation at Ser202 in vitro. J Biol Chem 284: 13422-13433. doi:10.1074/jbc.M901095200. PubMed: 19304664.
12. Brunden KR, Trojanowski JQ, Lee VM (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8: 783-793. doi:10.1038/nrd2959. PubMed: 19794442.
13. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A (2002) Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 99: 6364-6369. doi:10.1073/pnas.092136199. PubMed: 11959919. (Pubitemid 34493317)
14. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH et al. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-754. doi:10.1126/science. 1141736. PubMed: 17478722. (Pubitemid 46717684)
15. Iijima K, Gatt A, Iijima-Ando K (2010) Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease. Hum Mol Genet 19: 2947-2957. doi:10.1093/hmg/ddq200. PubMed: 20466736.
16. Yu W, Polepalli J, Wagh D, Rajadas J, Malenka R et al. (2012) A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Abeta on synapses and dendritic spines. Hum Mol Genet 21: 1384-1390. doi:10.1093/hmg/ ddr576. PubMed: 22156579.
17. Alonso AC, Zaidi T, Grundke-Iqbal I, Iqbal K (1994) Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A 91: 5562-5566. doi:10.1073/pnas.91.12.5562. PubMed: 8202528. (Pubitemid 24174368)
18. Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Yoshida H et al. (1995) Proline-directed and non-proline-directed phosphorylation of PHF-tau. J Biol Chem 270: 823-829. doi:10.1074/jbc.270.2.823. PubMed: 7822317.
19. Seubert P, Mawal-Dewan M, Barbour R, Jakes R, Goedert M et al. (1995) Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J Biol Chem 270: 18917-18922. doi:10.1074/jbc.270.32.18917. PubMed: 7642549.
20. Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ et al. (2007) Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 282: 23645-23654. doi:10.1074/jbc.M703269200. PubMed: 17562708. (Pubitemid 47311907)
21. Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E (1993) Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron 11: 153-163. doi:10.1016/0896-6273(93)90279-Z. PubMed: 8393323. (Pubitemid 23222542)
22. Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP et al. (2000) Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci U S A 97: 2910-2915. doi:10.1073/pnas.040577797. PubMed: 10706614. (Pubitemid 30159271)
23. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH (2003) Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40: 471-483. doi:10.1016/S0896-6273(03)00627-5. PubMed: 14642273. (Pubitemid 37494698)
24. Sakaue F, Saito T, Sato Y, Asada A, Ishiguro K et al. (2005) Phosphorylation of FTDP-17 mutant tau by cyclin-dependent kinase 5 complexed with p35, p25, or p39. J Biol Chem 280: 31522-31529. doi:10.1074/jbc.M504792200. PubMed: 15994305. (Pubitemid 41291895)
25. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15: 112-119. doi:10.1016/j.molmed.2009.01.003. PubMed: 19246243.
26. Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R et al. (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20: 27-39. doi:10.1093/emboj/20.1.27. PubMed: 11226152. (Pubitemid 32099099)
27. Sun W, Qureshi HY, Cafferty PW, Sobue K, Agarwal-Mawal A et al. (2002) Glycogen synthase kinase-3beta is complexed with tau protein in brain microtubules. J Biol Chem 277: 11933-11940. doi:10.1074/jbc.M107182200. PubMed: 11812770. (Pubitemid 34952752)
28. Sobue K, Agarwal-Mawal A, Li W, Sun W, Miura Y et al. (2000) Interaction of neuronal Cdc2-like protein kinase with microtubule-associated protein tau. J Biol Chem 275: 16673-16680. doi:10.1074/jbc.M000784200. PubMed: 10749861. (Pubitemid 30398896)
29. Nishimura I, Yang Y, Lu B (2004) PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116: 671-682. doi:10.1016/S0092-8674(04)00170-9. PubMed: 15006350. (Pubitemid 38326726)
30. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298: 789-791. doi:10.1126/science.1074069. PubMed: 12399581.
31. Sironi JJ, Yen SH, Gondal JA, Wu Q, Grundke-Iqbal I et al. (1998) Ser-262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK. FEBS Lett 436: 471-475. doi:10.1016/S0014-5793(98)01185-5. PubMed: 9801171. (Pubitemid 28482984)
32. Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E (1997) MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 89: 297-308. doi:10.1016/S0092-8674(00)80208-1. PubMed: 9108484. (Pubitemid 27199901)
33. Litersky JM, Johnson GV, Jakes R, Goedert M, Lee M et al. (1996) Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356. Biochem J 316 (2): 655-660. PubMed: 8687413. (Pubitemid 26182167)
34. Paudel HK (1997) The regulatory Ser262 of microtubule-associated protein tau is phosphorylated by phosphorylase kinase. J Biol Chem 272: 1777-1785. PubMed: 8999860.
35. Watanabe A, Hasegawa M, Suzuki M, Takio K, Morishima-Kawashima M et al. (1993) In vivo phosphorylation sites in fetal and adult rat tau. J Biol Chem 268: 25712-25717. PubMed: 8245007. (Pubitemid 23358184)
36. Vincent I, Rosado M, Davies P (1996) Mitotic mechanisms in Alzheimer's disease? J Cell Biol 132: 413-425. doi:10.1083/jcb.132.3.413. PubMed: 8636218. (Pubitemid 26053445)
37. Preuss U, Mandelkow EM (1998) Mitotic phosphorylation of tau protein in neuronal cell lines resembles phosphorylation in Alzheimer's disease. Eur J Cell Biol 76: 176-184. doi:10.1016/S0171-9335(98)80032-0. PubMed: 9716264. (Pubitemid 28365356)
38. Illenberger S, Zheng-Fischhöfer Q, Preuss U, Stamer K, Baumann K et al. (1998) The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease. Mol Biol Cell 9: 1495-1512. doi:10.1091/mbc.9.6.1495. PubMed: 9614189. (Pubitemid 28303492)
39. Delobel P, Flament S, Hamdane M, Mailliot C, Sambo AV et al. (2002) Abnormal Tau phosphorylation of the Alzheimer-type also occurs during mitosis. J Neurochem 83: 412-420. doi:10.1046/j.1471-4159.2002.01143.x. PubMed: 12423251. (Pubitemid 35191406)
40. Schipper HM, Agarwal-Mawal A, Paudel HK (1999) The topography and subcellular distribution of mitogen-activated protein kinase kinase1 (MEK1) in adult rat brain and differentiating PC12 cells. Neuroscience 93: 585-595. doi:10.1016/S0306-4522(99)00120-7. PubMed: 10465442. (Pubitemid 29329463)
41. Li T, Chalifour LE, Paudel HK (2007) Phosphorylation of protein phosphatase 1 by cyclin-dependent protein kinase 5 during nerve growth factor-induced PC12 cell differentiation. J Biol Chem 282: 6619-6628. PubMed: 17202132. (Pubitemid 47100889)
42. Yan GZ, Ziff EB (1995) NGF regulates the PC12 cell cycle machinery through specific inhibition of the Cdk kinases and induction of cyclin D1. J Neurosci 15: 6200-6212. PubMed: 7666202.
43. Cowley S, Paterson H, Kemp P, Marshall CJ (1994) Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77: 841-852. doi:10.1016/0092-8674(94) 90133-3. PubMed: 7911739. (Pubitemid 24187682)
44. Harada T, Morooka T, Ogawa S, Nishida E (2001) ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1. Nat Cell Biol 3: 453-459. doi:10.1038/35074516. PubMed: 11331872. (Pubitemid 32422080)
45. Fu H, Subramanian RR, Masters SC Fu H, Subramanian RR, Masters SC (2000) 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40: 617-647 doi:10.1146/annurev.pharmtox.40.1.617. PubMed: 10836149. doi:10.1146/annurev.pharmtox.40.1.617. PubMed: 10836149.
46. Berg D, Holzmann C, Riess O (2003) 14-3-3 proteins in the nervous system. Nat Rev Neurosci 4: 752-762. doi:10.1038/nrm1233. PubMed: 12951567. (Pubitemid 37280154)
47. Cheah PS, Ramshaw HS, Thomas PQ, Toyo-Oka K, Xu X et al. (2012) Neurodevelopmental and neuropsychiatric behaviour defects arise from 14-3-3zeta deficiency. Mol Psychiatry 17: 451-466. doi:10.1038/mp.2011.158. PubMed: 22124272.
48. Ramser EM, Wolters G, Dityateva G, Dityatev A, Schachner M et al. (2010) The 14-3-3zeta protein binds to the cell adhesion molecule L1, promotes L1 phosphorylation by CKII and influences L1-dependent neurite outgrowth. PLOS ONE 5: e13462. doi:10.1371/journal.pone.0013462. PubMed: 20976158.
49. Soulié C, Nicole A, Delacourte A, Ceballos-Picot I (2004) Examination of stress-related genes in human temporal versus occipital cortex in the course of neurodegeneration: involvement of 14-3-3 zeta in this dynamic process. Neurosci Lett 365: 1-5. doi:10.1016/j.neulet.2004.03.090. PubMed: 15234461. (Pubitemid 38952723)
50. Masliah E, Mallory M, Alford M, DeTeresa R, Hansen LA et al. (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56: 127-129. doi:10.1212/WNL.56.1.127. PubMed: 11148253. (Pubitemid 32059669)
51. Lu Y, Li T, Qureshi HY, Han D, Paudel HK (2011) Early growth response 1 (Egr-1) regulates phosphorylation of microtubule-associated protein tau in mammalian brain. J Biol Chem 286: 20569-20581. doi:10.1074/jbc.M111.220962. PubMed: 21489990.
52. Li T, Hawkes C, Qureshi HY, Kar S, Paudel HK (2006) Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. Biochemistry 45: 3134-3145. doi:10.1021/bi051635j. PubMed: 16519508. (Pubitemid 43376332)
53. Song W, Patel A, Qureshi HY, Han D, Schipper HM et al. (2009) The Parkinson disease-associated A30P mutation stabilizes alpha-synuclein against proteasomal degradation triggered by heme oxygenase-1 over-expression in human neuroblastoma cells. J Neurochem 110: 719-733. doi:10.1111/j.1471-4159.2009. 06165.x. PubMed: 19457084.
54. Paudel HK, Li W (1999) Heparin-induced conformational change in microtubule-associated protein Tau as detected by chemical crosslinking and phosphopeptide mapping. J Biol Chem 274: 8029-8038. doi:10.1074/jbc.274.12.8029. PubMed: 10075702.
55. Qureshi HY, Paudel HK (2011) Parkinsonian neurotoxin 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro. J Biol Chem 286: 5055-5068. doi:10.1074/jbc.M110.178905. PubMed: 21127069.
56. Li T, Paudel HK (2006) Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. Biochemistry 45: 3125-3133. doi:10.1021/bi051634r. PubMed: 16519507. (Pubitemid 43376331)
57. Pap M, Cooper GM (1998) Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J Biol Chem 273: 19929-19932. doi:10.1074/jbc.273.32.19929. PubMed: 9685326. (Pubitemid 28377539)
58. Jicha GA, Weaver C, Lane E, Vianna C, Kress Y et al. (1999) cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J Neurosci 19: 7486-7494. PubMed: 10460255. (Pubitemid 29404605)
59. Scott CW, Spreen RC, Herman JL, Chow FP, Davison MD et al. (1993) Phosphorylation of recombinant tau by cAMP-dependent protein kinase. Identification of phosphorylation sites and effect on microtubule assembly. J Biol Chem 268: 1166-1173. PubMed: 8419321. (Pubitemid 23019756)
60. Liu SJ, Zhang JY, Li HL, Fang ZY, Wang Q et al. (2004) Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain. J Biol Chem 279: 50078-50088. doi:10.1074/jbc.M406109200. PubMed: 15375165. (Pubitemid 39577819)
61. Taylor SS, Buechler JA, Yonemoto W (1990) cAMP-dependent protein kinase: framework for a diverse family of regulatory enzymes. Annu Rev Biochem 59: 971-1005. doi:10.1146/annurev.bi.59.070190.004543. PubMed: 2165385. (Pubitemid 120024460)
62. Hashiguchi M, Sobue K, Paudel HK (2000) 14-3-3zeta is an effector of tau protein phosphorylation. J Biol Chem 275: 25247-25254. doi:10.1074/jbc. M003738200. PubMed: 10840038.
63. Cassano S, Gallo A, Buccigrossi V, Porcellini A, Cerillo R et al. (1996) Membrane localization of cAMP-dependent protein kinase amplifies cAMP signaling to the nucleus in PC12 cells. J Biol Chem 271: 29870-29875. doi:10.1074/jbc.271. 47.29870. PubMed: 8939928. (Pubitemid 26389620)
64. Amieux PS, Howe DG, Knickerbocker H, Lee DC, Su T et al. (2002) Increased basal cAMP-dependent protein kinase activity inhibits the formation of mesoderm-derived structures in the developing mouse embryo. J Biol Chem 277: 27294-27304. doi:10.1074/jbc.M200302200. PubMed: 12004056. (Pubitemid 34951748)
65. Vinogradova TM, Lyashkov AE, Zhu W, Ruknudin AM, Sirenko S et al. (2006) High basal protein kinase A-dependent phosphorylation drives rhythmic internal Ca2+ store oscillations and spontaneous beating of cardiac pacemaker cells. Circ Res 98: 505-514. doi:10.1161/01.RES.0000204575.94040.d1. PubMed: 16424365.
66. Angelastro JM, Klimaschewski L, Tang S, Vitolo OV, Weissman TA et al. (2000) Identification of diverse nerve growth factor-regulated genes by serial analysis of gene expression (SAGE) profiling. Proc Natl Acad Sci U S A 97: 10424-10429. doi:10.1073/pnas.97.19.10424. PubMed: 10984536.
67. Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH (1998) New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 71: 2465-2476. PubMed: 9832145. (Pubitemid 28531257)
68. Layfield R, Fergusson J, Aitken A, Lowe J, Landon M et al. (1996) Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neurosci Lett 209: 57-60. doi:10.1016/0304-3940(96)12598-2. PubMed: 8734909. (Pubitemid 26150420)
69. Umahara T, Uchihara T, Tsuchiya K, Nakamura A, Iwamoto T et al. (2004) 14-3-3 proteins and zeta isoform containing neurofibrillary tangles in patients with Alzheimer's disease. Acta Neuropathol 108: 279-286. doi:10.1007/s00401-004- 0885-4. PubMed: 15235803. (Pubitemid 39317695)
70. Arendt T (2009) Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 118: 167-179. doi:10.1007/s00401-009-0536-x. PubMed: 19390859.
71. Honer WG (2003) Pathology of presynaptic proteins in Alzheimer's disease: more than simple loss of terminals. Neurobiol Aging 24: 1047-1062. doi:10.1016/j.neurobiolaging.2003.04.005. PubMed: 14643376.
72. Daly C, Ziff EB (1997) Post-transcriptional regulation of synaptic vesicle protein expression and the developmental control of synaptic vesicle formation. J Neurosci 17: 2365-2375. PubMed: 9065497. (Pubitemid 27137403)
73. Wheeler TC, Chin LS, Li Y, Roudabush FL, Li L (2002) Regulation of synaptophysin degradation by mammalian homologues of seven in absentia. J Biol Chem 277: 10273-10282. doi:10.1074/jbc.M107857200. PubMed: 11786535. (Pubitemid 34968143)
74. Lee DH, Goldberg AL (1998) Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 8: 397-403. doi:10.1016/S0962-8924(98)01346-4. PubMed: 9789328. (Pubitemid 28458705)
75. Ren QG, Liao XM, Chen XQ, Liu GP, Wang JZ (2007) Effects of tau phosphorylation on proteasome activity. FEBS Lett 581: 1521-1528. doi:10.1016/j.febslet.2007.02.065. PubMed: 17376439.
76. Huff LM, Sackett DL, Poruchynsky MS, Fojo T (2010) Microtubule-disrupting chemotherapeutics result in enhanced proteasome-mediated degradation and disappearance of tubulin in neural cells. Cancer Res 70: 5870-5879. doi:10.1158/0008-5472.CAN-09-4281. PubMed: 20587529.
77. Leugers CJ, Lee G (2010) Tau potentiates nerve growth factor-induced mitogen-activated protein kinase signaling and neurite initiation without a requirement for microtubule binding. J Biol Chem 285: 19125-19134. doi:10.1074/jbc.M110.105387. PubMed: 20375017.
78. Black MM, Aletta JM, Greene LA (1986) Regulation of microtubule composition and stability during nerve growth factor-promoted neurite outgrowth. J Cell Biol 103: 545-557. doi:10.1083/jcb.103.2.545. PubMed: 3733878. (Pubitemid 16055050)
79. Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ et al. (1996) Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383: 550-553. doi:10.1038/383550a0. PubMed: 8849730. (Pubitemid 26346185)
80. Iwai A (2000) Properties of NACP/alpha-synuclein and its role in Alzheimer's disease. Biochim Biophys Acta 1502: 95-109. doi:10.1016/S0925- 4439(00)00036-3. PubMed: 10899435.
81. Sadik G, Tanaka T, Kato K, Yamamori H, Nessa BN et al. (2009) Phosphorylation of tau at Ser214 mediates its interaction with 14-3-3 protein: implications for the mechanism of tau aggregation. J Neurochem 108: 33-43. doi:10.1111/j.1471-4159.2008.05716.x. PubMed: 19014373.
82. Hernández F, Cuadros R, Avila J (2004) Zeta 14-3-3 protein favours the formation of human tau fibrillar polymers. Neurosci Lett 357: 143-146. doi:10.1016/j.neulet.2003.12.049. PubMed: 15036595. (Pubitemid 38230951)
83. Sluchanko NN, Sudnitsyna MV, Seit-Nebi AS, Antson AA, Gusev NB (2011) Properties of the monomeric form of human 14-3-3zeta protein and its interaction with tau and HspB6. Biochemistry 50: 9797-9808. doi:10.1021/bi201374s. PubMed: 21978388.
84. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R et al. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30: 572-580. doi:10.1002/ana.410300410. PubMed: 1789684.
85. Sze CI, Troncoso JC, Kawas C, Mouton P, Price DL et al. (1997) Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol 56: 933-944. doi:10.1097/00005072-199708000-00011. PubMed: 9258263. (Pubitemid 27329114)
86. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G et al. (1999) Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci U S A 96: 3228-3233. doi:10.1073/pnas.96.6.3228. PubMed: 10077666. (Pubitemid 29148873)
87. Tarsa L, Goda Y (2002) Synaptophysin regulates activity-dependent synapse formation in cultured hippocampal neurons. Proc Natl Acad Sci U S A 99: 1012-1016. doi:10.1073/pnas.022575999. PubMed: 11792847. (Pubitemid 34106627)
88. El-Husseini AE, Schnell E, Chetkovich DM, Nicoll RA, Bredt DS (2000) PSD-95 involvement in maturation of excitatory synapses. Science 290: 1364-1368. PubMed: 11082065.
89. Mendez P, De Roo M, Poglia L, Klauser P, Muller D (2010) N-cadherin mediates plasticity-induced long-term spine stabilization. J Cell Biol 189: 589-600. doi:10.1083/jcb.201003007. PubMed: 20440002.
90. Schmid RS, Maness PF (2008) L1 and NCAM adhesion molecules as signaling coreceptors in neuronal migration and process outgrowth. Curr Opin Neurobiol 18: 245-250. doi:10.1016/j.conb.2008.07.015. PubMed: 18760361.
91. Brennan GP, Jimenez-Mateos EM, McKiernan RC, Engel T, Tzivion G et al. (2013) Transgenic overexpression of 14-3-3 zeta protects hippocampus against endoplasmic reticulum stress and status epilepticus in vivo. PLOS ONE 8: e54491. doi:10.1371/journal.pone.0054491. PubMed: 23359526.
92. Perathoner A, Pirkebner D, Brandacher G, Spizzo G, Stadlmann S et al. (2005) 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 11: 3274-3279. doi:10.1158/1078-0432.CCR-04-2207. PubMed: 15867223. (Pubitemid 40627875)
93. Qi W, Liu X, Qiao D, Martinez JD (2005) Isoform-specific expression of 14-3-3 proteins in human lung cancer tissues. Int J Cancer 113: 359-363. doi:10.1002/ijc.20492. PubMed: 15455356. (Pubitemid 40038701)
94. Fan T, Li R, Todd NW, Qiu Q, Fang HB et al. (2007) Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 67: 7901-7906. doi:10.1158/0008-5472.CAN-07-0090. PubMed: 17699796. (Pubitemid 47281386)
95. Wang B, Liu K, Lin HY, Bellam N, Ling S et al. (2010) 14-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer. Mol Cell Biol 30: 1508-1527. doi:10.1128/MCB.01335-09. PubMed: 20086099.
96. Kawamoto Y, Akiguchi I, Jarius C, Budka H (2004) Enhanced expression of 14-3-3 proteins in reactive astrocytes in Creutzfeldt-Jakob disease brains. Acta Neuropathol 108: 302-308. doi:10.1007/s00401-004-0892-5. PubMed: 15235801. (Pubitemid 39317697)
97. Chen XQ, Chen JG, Zhang Y, Hsiao WW, Yu AC (2003) 14-3-3gamma is upregulated by in vitro ischemia and binds to protein kinase Raf in primary cultures of astrocytes. Glia 42: 315-324. doi:10.1002/glia.10185. PubMed: 12730952. (Pubitemid 36702272)
98. Pirim I (1998) Ischemic rat brains contain immunoreactivity of 14-3-3 proteins. Int J Neurosci 95: 101-106. doi:10.3109/00207459809000653. PubMed: 9845020.
99. Malaspina A, Kaushik N, de Belleroche J (2000) A 14-3-3 mRNA is upregulated in amyotrophic lateral sclerosis spinal cord. J Neurochem 75: 2511-2520. PubMed: 11080204.
100. Satoh J, Yamamura T, Arima K (2004) The 14-3-3 protein epsilon isoform expressed in reactive astrocytes in demyelinating lesions of multiple sclerosis binds to vimentin and glial fibrillary acidic protein in cultured human astrocytes. Am J Pathol 165: 577-592. doi:10.1016/S0002-9440(10)63322-6. PubMed: 15277231. (Pubitemid 38971387)
101. Tzivion G, Gupta VS, Kaplun L, Balan V (2006) 14-3-3 proteins as potential oncogenes. Semin Cancer Biol 16: 203-213. doi:10.1016/j.semcancer. 2006.03.004. PubMed: 16725345. (Pubitemid 43810260)